A groundbreaking treatment for Alzheimer's is on the horizon! Eisai and Biogen have submitted a new drug application for LEQEMBI® in Japan, offering a unique subcutaneous formulation for early Alzheimer's disease.
But here's the game-changer: If approved, lecanemab would be the first and only anti-amyloid treatment in Japan that can be self-administered at home from the start of therapy for this debilitating disease. This is a significant advancement for patients and caregivers, providing a more convenient and accessible treatment option.
The application is based on comprehensive research, including multiple subcutaneous administration studies of lecanemab in the Phase 3 Clarity AD open-label extension. These studies confirmed that weekly subcutaneous injections of 500mg lecanemab provided equivalent exposure and similar clinical benefits to the current intravenous (IV) administration every two weeks. The subcutaneous formulation also demonstrated a comparable safety profile, with less than 2% of patients experiencing systemic injection-related reactions.
And this is the part most people miss: The potential approval of the subcutaneous formulation would not only offer patients and caregivers the convenience of at-home treatment but also reduce the burden on healthcare resources. It could streamline the Alzheimer's treatment pathway by minimizing the need for hospital visits and the resources required for IV administration, such as infusion preparation and nurse monitoring.
Alzheimer's disease is a complex condition characterized by the accumulation of amyloid beta (Aβ) and tau proteins, driven by a continuous neurotoxic process. LEQEMBI® is a powerful treatment that targets both protofibrils and amyloid plaques, which are believed to contribute to brain injury and cognitive decline. By addressing these key factors, LEQEMBI® has the potential to slow down the progression of Alzheimer's disease.
The collaboration between Eisai and Biogen has been instrumental in the development and commercialization of Alzheimer's treatments since 2014. Eisai leads the global development and regulatory submissions for lecanemab, while both companies co-commercialize the product, with Eisai having the final decision-making authority. This partnership has resulted in the approval of LEQEMBI® in 51 countries and regions, with ongoing regulatory reviews in 9 countries.
Controversy alert: While LEQEMBI® has shown promising results, it's essential to acknowledge that drug development and commercialization are high-risk endeavors. Early-stage clinical trial outcomes may not always translate to full approval, and the road to regulatory acceptance is often filled with uncertainties. This is a critical aspect to consider, especially for patients and families eagerly awaiting new treatment options.
Eisai and Biogen's commitment to Alzheimer's research is evident in their global efforts and collaborations. Eisai's corporate concept emphasizes prioritizing patients' well-being and reducing health disparities, while Biogen pioneers innovative science to deliver transformative medicines. Both companies actively engage in various activities to eliminate neglected tropical diseases, aligning with the United Nations' Sustainable Development Goals.
For more information, visit the official websites and social media channels of Eisai and Biogen, ensuring you access the content intended for your region. Stay informed and join the conversation as we eagerly await the potential approval of this groundbreaking treatment for Alzheimer's disease.
